OncoMatch/Clinical Trials/NCT07718620
HPV-associated Oropharyngeal Carcinoma (HPV-OPC)
Is NCT07718620 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for oropharyngeal carcinoma (opc).
This study focuses on the longitudinal monitoring of HPV infection in patients with head and neck cancers, particularly oropharyngeal carcinoma (OPC), using a new electrochemical detection method. This method has already been successfully developed and validated for cervical cancer. The aim of the project is to monitor the dynamics of HPV viral load before the start of treatment and during conservative radiation therapy or concurrent chemoradiation therapy. HPV will be analyzed from oral swabs, oral cavity washings, and plasma as part of a small prospective study. The results of the new method will be correlated with standard techniques, particularly qPCR. Longitudinal monitoring may contribute to the individualization and potential de-escalation of treatment in selected patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Prior therapy
Cannot have received: induction chemotherapy
Cannot have received: radiation therapy to the oropharynx
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07718620 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior induction chemotherapy, radiation therapy to the oropharynx disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages